2m 2m 2m 2m 2m 2m 2m
HUMACYTE (HUMA)
NASDAQ
$1.40-$0.005 (-0.36%)
Price as of Jun 03, 2026 7:54 PM EDT- $288.6MMarket Cap
- -46.74%1-Year Change
- BiotechnologyIndustry
HUMACYTE (HUMA)
$1.40-$0.005 (-0.36%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 1.4M N/A | N/A N/A | N/A N/A | N/A N/A | |
Cost of Revenue | 9.7M N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | -8.3M N/A | 0 N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -69.3M -21.78% | -88.6M +15.74% | -76.5M +21.01% | -63.3M +3.13% | |
Depreciation and Amortization Expense | 5.3M +4.39% | 5.1M -9.81% | 5.7M -8.00% | 6.2M -0.49% | |
Total Operating Expenses | 110.2M -3.69% | 114.4M +14.34% | 100.0M +16.14% | 86.1M +4.45% | |
Operating Profit | -108.1M -5.47% | -114.4M +14.34% | -100.0M +18.29% | -84.6M +4.15% | |
Interest Income | 2.6M -36.96% | 4.1M -24.93% | 5.5M +107.95% | 2.6M +16,331.25% | |
Interest Expense | -8.7M +12.99% | -7.7M +16.68% | -6.6M +6.44% | -6.2M +42.59% | |
Interest Income and Expense and Net | -6.1M +69.99% | -3.6M +217.67% | -1.1M -68.30% | -3.6M -17.57% | |
Total Nonoperating Income and Expense | 67.3M +296.20% | -34.3M +219.72% | -10.7M -114.78% | 72.6M +32.67% | |
Income before Taxes | -108.1M -5.47% | -114.4M +14.34% | -100.0M +18.29% | -84.6M +4.15% | |
Income Taxes | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -40.8M -72.54% | -148.7M +34.24% | -110.8M +825.83% | -12.0M -54.81% | |
Net Income from Continuing Operations Applicable to Common | -40.8M -72.54% | -148.7M +34.24% | -110.8M +825.83% | -12.0M -54.81% | |
Basic EPS and Net Income | -0.26 -79.37% | -1.26 +17.76% | -1.07 +791.67% | -0.12 -81.82% | |
Diluted EPS and Net Income | -0.26 -79.37% | -1.26 +17.76% | -1.07 +791.67% | -0.12 -81.82% | |
Basic Weighted Average Shares | 158.2M +33.49% | 118.5M +14.56% | 103.4M +0.36% | 103.1M +157.82% | |
Diluted Weighted Average Shares | 158.2M +33.49% | 118.5M +14.56% | 103.4M +0.36% | 103.1M +157.82% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 50.5M +12.37% | 44.9M -44.14% | 80.4M -46.29% | 149.8M -31.14% | |
Short-Term Investments | N/A N/A | N/A N/A | 0 -100.00% | 2.1M -73.66% | |
Cash and Cash Equivalents and Short-Term Investments | 50.5M +12.37% | 44.9M -44.14% | 80.4M -47.03% | 151.9M -32.65% | |
Total Current Assets | 67.8M +41.66% | 47.9M -42.53% | 83.3M -46.00% | 154.2M -32.76% | |
Accumulated Depreciation | 41.3M +14.53% | 36.1M +15.20% | 31.3M +19.65% | 26.2M +28.09% | |
Property and Plant and Equipment and Net | 18.5M -19.59% | 23.1M -13.92% | 26.8M -10.81% | 30.0M -14.26% | |
Total Long-Term Assets | 672,000 -46.28% | 1.3M +48.75% | 841,000 -97.20% | 30.0M -14.26% | |
Total Assets | 116.4M -15.60% | 137.9M +7.53% | 128.2M -37.24% | 204.3M -28.70% | |
Income Taxes Payable | 762,000 -34.48% | 1.2M -23.39% | 1.5M -18.26% | 1.9M -16.91% | |
Total Short-Term Debt | N/A N/A | N/A N/A | 0 -100.00% | 8.6M N/A | |
Total Current Liabilities | 18.4M -7.93% | 20.0M +8.19% | 18.4M -5.81% | 19.6M +77.19% | |
Total Long-Term Debt | 35.4M -44.05% | 63.4M +64.13% | 38.6M +89.81% | 20.3M -25.68% | |
Total Long-Term Liabilities | 1.6M +61.04% | 983,000 +24.59% | 789,000 +10.81% | 712,000 -39.61% | |
Total Liabilities | 113.3M -40.56% | 190.5M +66.15% | 114.7M +31.25% | 87.4M -46.84% | |
Retained Earnings | -726.8M +5.95% | -686.0M +27.67% | -537.3M +25.97% | -426.5M +2.89% | |
Total Stockholders Equity | 3.1M +105.90% | -52.7M -488.82% | 13.5M -88.42% | 116.9M -4.29% | |
Total Shares Outstanding | 193.0M +48.43% | 130.0M +25.42% | 103.7M +0.43% | 103.2M +0.22% | |
Cash Flow | |||||
Cash from Operating Activities | -105.0M +7.05% | -98.1M +33.85% | -73.3M +3.06% | -71.1M -12.39% | |
Capital Expenditures | 884,000 -43.77% | 1.6M -31.05% | 2.3M +117.56% | 1.0M +376.36% | |
Cash from Investing Activities | -884,000 -43.77% | -1.6M +808.67% | -173,000 -103.57% | 4.8M +158.94% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 61.5M -46.15% | 114.2M +2,433.46% | 4.5M +411.69% | -1.4M -100.54% | |
Financials Ratio | |||||
Gross Margin | -598.49% N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -7,785.24% N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | -32.12% -71.26% | -111.77% +67.75% | -66.63% +1,266.60% | -4.88% -64.30% | |
Return on Equity | 164.78% -78.32% | 760.17% +547.67% | -169.81% +1,596.65% | -10.01% -75.96% | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 3.69 +53.85% | 2.40 -46.88% | 4.52 -42.67% | 7.88 -62.05% | |
Cash Ratio | 2.75 +22.05% | 2.25 -48.37% | 4.36 -42.97% | 7.65 -61.14% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | 2.85 +1,052.71% | 0.25 +10.36% | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | 0.30 +112.72% | 0.14 +48.17% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow